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Serous cystadenoma (also known as glycogen-rich
adenoma including macrocystic, microcystic or
oligocystic adenoma) is a rare, usually benign
neoplasm that occurs more commonly in older
woman, with a mean age at diagnosis of about 
66 years (range, 34–91 years), and with a female
predominance (70%).1 These tumors are often
solitary but may be multifocal, which are more
common in patients with von Hippel–Lindau
(VHL) disease. They may also present simultane-
ously with other pancreatic neoplasms such as
pancreatic duct adenocarcinoma or other en-
docrine neoplasms. Here, we report two cases 




A 64-year-old woman, with a history of diabetes
mellitus and asthma, was found incidentally to
have a pancreatic tumor by abdominal computed
tomography (CT). She had right upper quadrant
pain but no nausea or poor appetite. Abdominal
magnetic resonance imaging (MRI) revealed one
cystic lesion in the pancreatic neck (Figure 1A). As
a result of increased serum level of carbohydrate
antigen 19-9 (376.8 U/mL; normal, < 37 U/mL)
and fear of pancreatic malignancy or branch-type
intraductal papillary mucinous neoplasm, distal
pancreatectomy was performed.
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Combined Pancreatic Endocrine Tumor and
Serous Cystadenoma
Min-Shu Hsieh,1 Kao-Lang Liu,2 Yu-Wen Tien,3 Chia-Tung Shun4*
Pancreatic serous cystadenomas account for 1–2% of all exocrine pancreatic tumors, and endocrine tumors
account for 1–2% of all pancreatic neoplasms. The combination of pancreatic serous cystadenoma and
endocrine tumor is even rarer. Here, we report two cases of combined pancreatic serous adenoma and 
endocrine tumor. One was a 64-year-old woman with serous cystadenoma and pancreatic endocrine
tumor. The other case was a 28-year-old woman with von Hippel–Lindau disease with combined pancreatic
serous oligocystic adenoma and well-differentiated malignant endocrine carcinoma. Reviewing the literature,
we found 15 similar cases that showed two different age distributions and clinical presentations. Careful
examination of benign serous cystadenoma should be kept in mind during clinical practice, to rule out 
the possibility of combined malignant endocrine tumor. In addition, von Hippel–Lindau disease should
also be suspected when a young adult presents with combination of pancreatic serous cystadenoma and
endocrine tumor. [J Formos Med Assoc 2009;108(9):739–745]
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The specimen submitted for pathological 
examination consisted of pancreatic tissue that
measured 3.3 × 3 × 1.5 cm in size. Grossly, a white,
spongy-like, well-defined tumor that measured
about 1.3 × 1 cm was noted. Microscopically, 
it showed a serous cystadenoma composed of 
irregular-shaped cysts lined by cuboidal epithe-
lium, without a definite central stellate scar
(Figure 2A). Additionally, a small pancreatic en-
docrine tumor (0.6 × 0.5 cm) formed by neoplas-
tic cells with monotonous round nuclei and
arranged in a trabecular pattern was found (Figure
2B). Immunohistochemically, it stained diffusely
positive to chromogranin and synaptophysin.
Combined serous cystadenoma and pancreatic
endocrine tumor were diagnosed. After a follow-
up period of 14 months, the patient remained 
disease-free.
Case 2
A 28-year-old woman, without a family history of
VHL disease, suffered from intermittent headache.
Brain MRI in 2007 revealed a cystic lesion of the
right cerebellum, which was shown to be heman-
gioblastoma after tumor excision. In addition,
abdominal MRI disclosed numerous small pan-
creatic cysts, and a nodular solid mass of about
2.3 cm in diameter in the pancreatic uncinate
process (Figures 1C and 1D). She denied any
symptoms of abdominal discomfort or decreased
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Figure 1. Case 1: contrast-enhanced (Gd-diethylenetriamine penta-acetic acid) axial magnetic resonance imaging shows:
(A) a 1.3-cm hypovascular cystic tumor in the pancreatic neck (arrow); and (B) a smaller persistent enhanced tumor in
the pancreatic body (arrow), consistent with serous cystadenoma and endocrine tumor. Case 2 (C and D): T2-weighted
coronal magnetic resonance and contrast-enhanced images reveal diffuse cystic lesions in the pancreas. A large cystic
tumor at the lateral aspect of the pancreatic head without enhancement (white arrows), and a solid tumor in the pancre-
atic uncinate process with persistent enhancement (yellow arrows) were identified, consistent with serous oligocystic
adenoma and well-differentiated malignant endocrine tumor, respectively.
appetite. No jaundice or abdominal mass could be
found during physical examination. Liver function
tests and tumor markers were normal. Whipple’s
operation was performed under the impression
of a malignant pancreatic head tumor.
Pathologically, the specimen included a 5 ×
4 × 4-cm proximal portion of pancreas and a 21-
cm length of small bowel. The pancreatic tissue
showed multiple cystic lesions that measured up
to 2.5 × 2.0 × 1.2 cm in size, with clear fluid con-
tent (Figure 2C). No central or stellate scar could
be seen within the cystic lesion. Also, one well-
circumscribed, light-yellow mass that measured
2.8 × 2.5 × 2.2 cm was noted in the pancreatic
parenchyma (Figure 2D). The pancreatic duct was
not dilated and the common bile duct was patent.
Microscopically, the nodular lesion was com-
posed of monotonous neoplastic cells arranged
in nests or acinar structures. These cells showed
round nuclei with a fine, or salt-and-pepper
chromatin pattern, and a moderate amount of
eosinophilic cytoplasm, consistent with features of
neuroendocrine cells. It presented as an infiltra-
tive growth pattern and replaced previous pan-
creatic parenchyma and surrounding soft tissue.
Lymphatic permeation and perineural invasion
were also noted (Figure 3A). Marked stromal
sclerotic change with dense collagen bundles in
the central area was also discernible. Immuno-
histochemically, the tumor cells stained positive
for synaptophysin (Figure 3B) and chromogranin-
A. According to its size (> 2 cm in diameter) and
its invasive growth pattern, a well-differentiated
malignant pancreatic endocrine tumor was con-
sidered. In addition, multiple cystic lesions lined
by cuboidal to low columnar epithelial cells with
Pancreatic endocrine tumor and cystadenoma
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Figure 2. (A) Serous cystadenoma in case 1, composed of multiple small cysts without a central stellate scar. (B) Well-
differentiated pancreatic endocrine tumor in case 1, with smaller size and well-defined tumor borders (arrows). 
(C) Serous oligocystic adenoma in case 2, composed of variable-sized cysts and no central scar. (D) Well-differentiated
pancreatic endocrine carcinoma in case 2, with intimate association with serous cystadenoma (arrow) and infiltrative
growth pattern, which replaced adjacent soft tissue and lymph nodes (arrowhead).
periodic-acid–Schiff-positive clear cytoplasm and
small round nuclei were found (Figures 3C and
3D). No central stellate scar was present. Serous
oligocystic cystadenoma was considered. Clinical
diagnosis of VHL disease in this patient was based
on the presence of cerebellar hemangioblastoma
and well-differentiated malignant pancreatic en-
docrine tumor. She remained disease-free for 
8 months after surgery.
Discussion
Pancreatic cystic lesions are being discovered in-
creasingly by widely used modern imaging tech-
niques, such as abdominal sonography, CT or
MRI, before the appearance of clinical symptoms
caused by local mass effects such as abdominal
pain, palpable mass, common bile duct obstruc-
tion, or hemorrhage.
We report two rare cases of combined pan-
creatic endocrine tumor and serous oligocystic
cystadenoma. In addition to the first report by
Heresbach et al2 in 1993, we found 13 similar
cases published in the English-language literature
in PubMed (Table 1).3–12 Pancreatic endocrine
tumor may be separated or mixed within the
serous cystadenoma. The ages ranged from 28 to
78 years (mean, 53.4 years), with a female:male
ratio of 6:1, similar to the study of Blandamura
et al,11 who reviewed 10 cases (mean age, 55.2
years) from 1993 to 2006 (case numbers 1, 3–8
and 10–12 in Table 1).
We found that these patients could be separated
further into two groups according to the pres-
ence of VHL disease (Table 2). These two groups
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Figure 3. (A) Perineural invasion of endocrine carcinoma, which is an important diagnostic finding for malignancy (100×).
(B) Pancreatic endocrine carcinoma stains positively for synaptophysin (100×). (C) Lining epithelial cells of serous 
cystadenoma show clear cytoplasm and monotonous round nuclei (100 ×). (D) Lining cuboidal cells with clear cytoplasm
and glycogen content are confirmed by positive periodic acid–Schiff stain (200×).
had a different clinicopathological presentation.
The age distribution in VHL patients (3 cases; age
range, 28–31 years; mean age, 29.3 years) was
significantly younger than that of the non-VHL
patients (11 cases; age range, 47–78 years; mean
age, 60.0 years). The common pathological find-
ings in VHL patients are pancreatic endocrine
neoplasms in the pancreatic head, with a high
Pancreatic endocrine tumor and cystadenoma
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Table 1. Clinicopathological features of reviewed cases
Case [Ref] Sex/age (yr) Pathologic feature of serous cystadenoma Pathologic feature of endocrine tumor
1 [2] F/70 Pancreatic head Pancreatic body, well-differentiated, benign
2 [3] NA NA NA VHL
3 [4] F/47 7.5 cm SCT at pancreatic head 1.5 cm, within SCT, well-differentiated, benign
4 [5] F/67 16 cm, single tumor, diffusely replacing 2.8 cm, within SCT, invading duodenum, 
pancreas well-differentiated, carcinoma
5 [6] F/49 13 cm at head 1.0 cm, within SCT, well-differentiated, benign
6 [7] F/29 Diffusely involving body and tail, 30 cm 2.0 cm at pancreatic head, uncertain VHL
malignant potential
7 [8] M/53 4.5 cm at pancreatic head 1.5 cm within SCT, well-differentiated, benign
8 [9] F/78 14 cm involving body and tail 5 cm within SCT, well-differentiated, uncertain 
malignant potential
9 [10] M/52 1.5 cm SCT in pancreatic head 0.3 cm PET in tail, well-differentiated, benign
10 [11] F/71 2.5 cm SCT in body 1.1 cm PET in body
11 [11] F/57 2.3 cm SCT in body 0.5 cm PET in body
12 [11] F/31 Small, multiple, diffusely involving 4.0 cm PET in head, well-differentiated, VHL
whole pancreas carcinoma
13 [12] F/52 10 cm SCT in body Within SCT, well differentiated
14 (case 1) F/64 1.3 cm in body 0.6 cm in body, well-differentiated, benign
15 (case 2) F/28 Small, multiple, diffusely involving 2.3 cm at uncinate process, partially mixed VHL
whole pancreas with SCT
VHL = von Hippel–Lindau syndrome; NA = not applicable; SCT = serous cystic tumor; PET = pancreatic endocrine tumor.
Table 2. Clinicopathological characteristics of von Hippel–Lindau (VHL) and non-VHL patients
Factors VHL non-VHL p
Case number* 3 11
Age range (yr; mean ± SD)* 28–31 (29.3 ± 1.53) 47–78 (60 ± 10.4) 0.0000011254 (< 0.05)
Sex (female:male) 3:0 9:2
Histological grading or PET
Benign 8
Uncertain behavior 1 1
Carcinoma 2 2
Size (cm)† 2.77 ± 1.08 1.59 ± 1.48 0.2
Numbers of serous cystadenoma
Diffuse involvement 3 0
Single tumor 0 11
*Excluding case 2 because of absence of applicable data; †excluding cases 1, 2 and 13 because of absence of applicable data.
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prevalence of well-differentiated endocrine car-
cinoma, surrounded by multiple foci of serous
cystadenoma spread diffusely in the pancreas.
On the contrary, most non-VHL patients show
well-differentiated benign endocrine tumors of
smaller size (not statistically significant) than
those found in VHL patients, and all are associ-
ated with a single serous cystadenoma.
It is well known that serous cystadenoma and
pancreatic endocrine tumor are classical presen-
tations of VHL disease. VHL disease is an autoso-
mal dominant, familial neoplastic disease, which
predisposes affected persons to retinal angioma,
cerebellar hemangioblastoma, clear cell renal cell
carcinoma, spinal hemangioblastoma, pheochro-
mocytoma, pancreatic cysts, serous cystadenoma,
or endocrine neoplasm. It is caused by germline
loss-of-function mutations in the VHL tumor sup-
pressor gene. Approximately 20% of cases have
new mutations without a family history. The re-
ported frequency of pancreatic involvement in
VHL disease is 17–56%. In the study carried out by
Hammel et al,13 122 of 155 patients (77.2%) with
VHL disease showed pancreatic involvement;
91.1% had true cysts, 12.3% had serous cystade-
noma, 12.3% had endocrine tumors, and 11.5%
(17 cases) had combined lesions. Of the 17 com-
bined lesions, 11 comprised an association of
serous cystic tumors and endocrine neoplasms.
In 389 VHL patients studied by Libutti et al,14
44 (11%) had pancreatic endocrine tumors, and
five (11.4%) had metastatic disease. In 633 VHL
patients investigated by Blansfield et al,15 108
(17%) had pancreatic endocrine tumors, and
nine (8.3%) had metastasis.
There are two hypotheses to explain the com-
bination of two pancreatic tumors. One suggests
biphasic differentiation from a common progen-
itor tumor cell,4 supported by the observation of
nesidioblastosis, a non-neoplastic disorder with
coincident epithelial and endocrine differentia-
tion. This may explain cases in which both tu-
mors are mixed together intimately, but cannot
explain those with separated lesions. The other
explanation is collision tumors, which develop
separately and probably arise from a predisposing
genetic disorder, such as VHL disease.
Pancreatic serous cystic tumor is usually a be-
nign lesion and may be the early clinical presen-
tation in VHL patients. Although it is rare, the
possibility of combined endocrine tumors should
be kept in mind during clinical imaging follow-up
or processing the resected specimen. As a result of
the uncertain behavior of pancreatic endocrine
tumors, careful sampling is needed to rule out this
potential malignant disease from a benign serous
cystic tumor of the pancreas.
In summary, we report two cases of com-
bined pancreatic endocrine tumor and serous
cystadenoma. It is a rare condition and should
raise suspicion of underlying VHL disease when
it appears in young adults. As a result of increased
frequency of malignant endocrine tumors in VHL
disease, close clinical follow-up and adequate 
resection are mandatory.
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